Asthma
Conditions
Keywords
Cost-effectiveness analysis, Symbicort
Brief summary
This study is an economic evaluation of Symbicort (Budesonide/formoterol) as maintenance and reliever therapy (SMART) versus its competitive alternatives. The aims of this study are: * To estimate the relative effectiveness of each one of the alternatives in the management of patients with moderate to severe asthma through a systematic review for the following outcomes: * Cumulative incidence of asthma severe exacerbations symptoms * Safety of each alternative (frequency of adverse events and complications due to the medications) * To estimate the direct medical costs of treating with each pharmacologic alternative: Symbicort as SMART versus increased use of inhaled corticosteroids or Adding long-acting inhaled beta 2 agonist plus inhaled corticosteroids. * To create a decision analysis model (decision tree) that allows comparisons between the alternatives on expected values and costs. * To calculate the average and incremental cost-effectiveness ratios. * To carry out a sensitivity analysis to test de robustness of the cost-effectiveness results allowing for reasonable changes in expected values and costs.
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
COHORT
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Moderate to severe asthma.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Estimate incremental cost-effectiveness ratio using Symbicort as Maintenance and Reliever Therapy in the pharmacologic management of patients when compared with competitive alternatives | 12 months |
| Incremental cost-effectiveness ratio from using Symbicort as symbicort as Maintenance and Reliever Therapy when compared with its competitive alternatives | 12 Months |
Countries
Colombia
Outcome results
None listed